 LTCI increases the production of CD-4+ T-cells and can subsequently overcome this immunosuppression.LTCI, manufactured by T-Cyte Therapeutics, has been conditionally approved by the United States Department of Agriculture (USDA) as an aid in the treatment of cats infected with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV), and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, or thrombocytopenia.Peer-reviewed literature disputes the benefit claims from the manufacturer.